PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.

[1]  Y. Jeon,et al.  Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. , 2015, European journal of cancer.

[2]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[3]  Jaime Rodriguez-Canales,et al.  A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition , 2015, Clinical Cancer Research.

[4]  H. Min,et al.  Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status , 2015, Modern Pathology.

[5]  Olfat Al-Harazi,et al.  Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells , 2015, Molecular Cancer.

[6]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[7]  Qi Zhao,et al.  PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma , 2015, Medical Oncology.

[8]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[9]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[10]  Y. Jeon,et al.  Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. , 2015, Lung cancer.

[11]  Guotong Xu,et al.  Epithelial phenotype as a predictive marker for response to EGFR‐TKIs in non‐small cell lung cancer patients with wild‐type EGFR , 2014, International Journal of Cancer.

[12]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[13]  T. Niki,et al.  Immunohistochemical analysis of the expression of E‐cadherin and ZEB1 in non‐small cell lung cancer , 2014, Pathology international.

[14]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[15]  Lixia Diao,et al.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.

[16]  Kwan-Kyu Park,et al.  Transcription factors related to epithelial mesenchymal transition in tumor center and margin in invasive lung adenocarcinoma. , 2014, International journal of clinical and experimental pathology.

[17]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[18]  Travis J Cohoon,et al.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, Cancer discovery.

[19]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[20]  William Pao,et al.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[22]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[23]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[24]  M. Tatari,et al.  EMT as the ultimate survival mechanism of cancer cells. , 2012, Seminars in cancer biology.

[25]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[26]  H. Uramoto,et al.  Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. , 2011, Lung cancer.

[27]  M. Azuma,et al.  Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis. , 2011, Cancer research.

[28]  M. Azuma,et al.  B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. , 2011, Cancer research.

[29]  Yan Zhang,et al.  Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer , 2010, Cellular and Molecular Immunology.

[30]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[31]  Yutaka Kawakami,et al.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. , 2009, Cancer cell.

[32]  T. Okazaki,et al.  PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.

[33]  J. Minna,et al.  Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. , 2006, Cancer research.

[34]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.